A blood test that its maker says can flag signs of more than 50 types of cancer from a single draw is getting its highest-stakes review yet: a vote Wednesday from a federal advisory panel that could determine whether it ever becomes a routine part of American health care.

The FDA's Molecular and Clinical Genetics Panel, part of the agency's Medical Devices Advisory Committee, is meeting to evaluate the premarket approval application for Grail's Galleri test, a multi-cancer early detection screen the company submitted to the FDA on Jan. 29, 2026. It's the first test of its kind — designed to look for cancer-specific DNA methylation patterns shared across dozens of cancer types — to reach a full FDA advisory committee review.

How the test works, and its limits

Galleri is built to detect cancer signals in the bloodstream before symptoms appear, including cancers such as pancreatic, esophageal and ovarian cancer that have no standard screening test today. Grail has always stressed that Galleri is meant to supplement, not replace, existing guideline-recommended screenings like mammograms and colonoscopies — a distinction likely to come up repeatedly as the panel weighs the strength of the clinical evidence, according to a review of the case by STAT News.

Because it would be the first multi-cancer early detection, or MCED, test to win a green light from an FDA panel, Wednesday's vote carries weight well beyond Grail's own business. Regulators and outside scientists say the standard the panel sets for evidence of safety and effectiveness will likely shape how the FDA treats a wave of rival MCED tests already in development at other companies.

THE TEST IS INTENDED TO BE USED IN ADDITION TO, NOT AS A REPLACEMENT FOR, GUIDELINE-RECOMMENDED SCREENING.

There's also a financial dimension patients are watching closely. Galleri currently costs $949 out of pocket and is not broadly covered by insurance. An FDA approval wouldn't automatically trigger reimbursement, but it would be a major step toward the kind of regulatory status that insurers typically require before agreeing to pay for a screening test, according to NPR's coverage of the review.

Patient advocacy groups and some oncologists are expected to testify in favor of approval, arguing that even an imperfect early-warning tool could save lives by catching aggressive cancers sooner. Other medical experts have raised concerns about false positives, the anxiety and unnecessary follow-up testing they can trigger, and whether the current data proves the test actually improves survival rather than just detecting cancer earlier without changing outcomes.

The advisory panel's vote isn't binding — the FDA makes the final approval decision — but the agency typically follows its advisory committees' recommendations. A decision on Grail's application is expected in the coming months.